Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition
Company Remains Confident That Future Launches Will See It Meet Ambitious Targets
Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
